Morning Movers
Watch us on YouTube Live at 8:30AM EST

HOOD.NQ -0.12%
Robinhood Markets Inc – Little changed premarket after a nice recovery rally Thursday, in its daily update Cathie Wood Ark Invest Frund showed asset managers added about $34.2 mln worth of HOOD shares in her ARK Fintech Innovation ETF and ARK Next Generation Internet ETF ARKW.P this week. ARK Invest has also added 3.2 mln shares of automation software co UiPath Inc and 1.1 mln shares of digital cell biology co Berkeley Lights Inc to its portfolio this week.

Squeeze Stocksx – Back on watch after another volatile session Thursday, highly shorted SmileDirect shares have become one of the latest favorites of the retail crowd trading up more than 8% premarket while this week’s other main high-flyer IRNT shares are sharply lower to start. IRNT, BBIG, GREE, AMC, SDC

ASAN.NY 0.79%
Asana Inc – Monster move to ATH midday yesterday, quiet premarket but holding the top end of yesterday’s trading range.

BYND.NQ -0.59%
Beyond Meat Inc – Reversed early weakness to close slightly lower Thursday, Piper Sandler downgraded the stock but mid-afternoon BYND announced it will supply McDonald’s in Netherlands with its McPlant product as it rolls out to another market.

LCID.NQ 5.57%
Lucid Group – Higher premarket for the third straight session, Lucid Group Inc’s Air Dream Edition Range luxury sedan has received U.S. government certification for a range of 520 miles, the electric vehicle maker said on Thursday.

BROS.NY -0.19%
Dutch Bros – This week’s hottest IPO remains on watch after a second straight day of strength yesterday. Shares have now doubled from their $23 IPO price BROS closed up 59.5% on Weds after co sold 21.1 mln shares well above expectations.

TTWO.NQ -1.24%
Take-Two Interactive Software – Brokerage BMO cuts rating to “market perform” from “outperform”; cuts PT to $150 from $225.

IPHA.NQ 31.13%
Innate Pharma SA – Monalizumab data from coast trial presented at esmo congress 2021, results showed monalizumab in combination with durvalumab improved progression-free survival and objective response rate versus durvalumab alone. Astrazeneca informed innate it plans to start registrational study with monalizumab in combination with durvalumab for unresectable, stage iii non-small cell lung cancer.

CRVS.NQ 52.65%
Corvus Pharmaceuticals – Shares of the drug developer are sharply higher premarket after late on Thursday regulators in China accepted an application to start an early-stage trial of CPI-818, its oral treatment for relapsed/refractory T-cell lymphomas.

Leave a Reply

Your email address will not be published.